Trial Profile

A Randomized, Open-label, Phase 2 Study to Evaluate Safety and Efficacy of DUR-928 in Subjects With Primary Sclerosing Cholangitis (PSC)

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 19 Oct 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Larsucosterol (Primary)
Indications Primary sclerosing cholangitis
Focus Adverse reactions; Therapeutic Use
Sponsors DURECT Corporation

Most Recent Events

14 Jul 2021 According to a DURECT Corporation media release, data will be presented at the Epigenetic Therapeutic Targets Summit.
07 Jan 2019 According to a DURECT Corporation media release, the company has decided to discontinue this trial due to slow enrollment rate.
07 Jan 2019 Status changed from recruiting to discontinued, according to a DURECT Corporation media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com